Investment
Features
FeesSafety
Academy
More
Pluang+

Upexi posts better-than-expected Q4 EPS but misses revenue targets amid weak digital asset markets.

Company Fundamentals
18 Sep 2026
Gordon Thompson
View Source
Neutral
Upexi posts better-than-expected Q4 EPS but misses revenue targets amid weak digital asset markets.

Upexi reported a Q4 2026 EPS of -$0.02, beating analyst expectations of -$0.11 due to strong cost management. However, the company's revenue fell short at $3.15 million versus the estimated $5.80 million, impacted by subdued digital asset markets, especially Solana. Despite challenges, Upexi improved its financial health by increasing cash reserves to $5.80 million and holding a substantial Solana treasury valued at $165.30 million. The company continues to focus on efficiency and debt reduction as it navigates a difficult market environment.

Upexi's Q4 2026 earnings report provides context for market conditions. For readers following US stocks on Pluang, here is the market snapshot as of Sep 18, 2026 19:01 WIB: Out of 150 priced US stocks, 59 rose and 85 fell. Nokia Corp (NOK) rose 1.60% to USD 10.78 with a typical hold time of 64 days and 62% buy order activity. Accenture plc (ACN) declined 1.55% to USD 187.35 with a typical hold time of 131 days. Meta Platforms Inc (META) increased 1.51% to USD 692.61 with a typical hold time of 126 days and 74% sell order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App